BioTuesdays

Tag - KZIA

Kazia Therapeutics New

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

Kazia

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...